Lonnie Moulder

Mr. Leon O.
Moulder is a Chairman & Chief Executive Officer at Zenas BioPharma, Inc., a Managing Member at Tellus BioVentures LLC, a Chairman at Dianthus Therapeutics OpCo, Inc., a Chairman at Temple University Japan, a Chief Executive Officer at Zenas BioPharma (USA) LLC and a Member at The University of Chicago Booth School of Business.
He is on the Board of Directors at Zai Lab Ltd., Aegle Therapeutics Corp., Helsinn SA, Interius BioTherapeutics, Inc., Navrogen, Inc., Praeventix, Inc., TamuroBio, Inc., The Fox Chase Cancer Center, viTToria Biotherapeutics, Inc. and Temple University (Pennsylvania).
Mr. Moulder was previously employed as a Chairman by Dianthus Therapeutics, Inc., a Chairman by Trevena, Inc., a Chief Executive Officer & Director by Tesaro, Inc., a Vice Chairman, President & Chief Executive Officer by Abraxis BioScience, Inc., a Vice Chairman by Eisai Corp.
of North America, a President & Chief Executive Officer by MGI PHARMA Biologics, Inc., a President, Chief Executive Officer & Director by MGI PHARMA, Inc., a VP-Business Development & Commercial Affairs by COULTER CELLULAR THERAPIES INC, a Director-Oncology & Anti Infective Products Group by Hoechst Marion Roussel, Inc., a Principal by Marion Laboratories, a Principal by Marion Merrell Dow Pharmaceutical, Inc., and a Clinical Pharmacist by Temple University Hospital, Inc. He also served on the board at Helsinn Healthcare SA, Cubist Pharmaceuticals, Inc., Biotechnology Innovation Organization and Mirati Therapeutics, Inc. He received his undergraduate degree from Temple University (Pennsylvania) and an MBA from The University of Chicago Booth School of Business.